 SHANGHAI and HONG KONG, Aug. 23, 2021 PRNewswire -- Antengene Corporation Limited Antengene, SEHK: 6996.HK, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class andor best-in-class therapeutics in hematology and oncology, today announced that Chinas National Medical Products Administration has approved a Phase II study of selinexor XPOVIO for the treatment of patients with myelofibrosis MF. MF is a clonal bone narrow neoplasm which can emerge either as primary MF PMF, polycythemia vera PV or essential thrombocythemia ET. 